FLI1 gene influences lesion size and skin test may predict therapeutic response in cutaneous leishmaniasis
- PMID: 32130370
- PMCID: PMC7064323
- DOI: 10.1590/0074-02760190361
FLI1 gene influences lesion size and skin test may predict therapeutic response in cutaneous leishmaniasis
Abstract
Genes associated with wound healing have been shown to be risk factors for cutaneous leishmaniasis (CL) which is caused by Leishmania braziliensis. In this study, we examined whether the genes previously associated with CL influenced the clinical outcome. Patients were genotyped and retrospectively classified as responders, who were cured with a single course of pentavalent antimony (Sbv), or as refractories, who did not respond to Sbv. Patients characterised as responders showed a stronger response to the leishmanin skin test (LST) when compared to the refractory subjects (p = 0.0003). Furthermore, we observed an association between the FLI1 CC genotype and an increased size of ulcers (p = 0.0170). We suggest that the leishmanin skin test may be a predictive tool for therapeutic outcome and reinforce FLI1 as a potential influencer of susceptibility and lesion size in CL.
Figures
Similar articles
-
Molecular epidemiology and in vitro evidence suggest that Leishmania braziliensis strain helps determine antimony response among American tegumenary leishmaniasis patients.Acta Trop. 2018 Feb;178:34-39. doi: 10.1016/j.actatropica.2017.10.010. Epub 2017 Oct 16. Acta Trop. 2018. PMID: 29042262 Free PMC article.
-
Wound healing genes and susceptibility to cutaneous leishmaniasis in Brazil.Infect Genet Evol. 2012 Jul;12(5):1102-10. doi: 10.1016/j.meegid.2012.03.017. Epub 2012 Mar 28. Infect Genet Evol. 2012. PMID: 22554650 Free PMC article.
-
Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.Infect Immun. 2009 May;77(5):2022-9. doi: 10.1128/IAI.01513-08. Epub 2009 Feb 23. Infect Immun. 2009. PMID: 19237520 Free PMC article.
-
Management of cutaneous leishmaniasis.Curr Opin Infect Dis. 2001 Apr;14(2):151-4. doi: 10.1097/00001432-200104000-00007. Curr Opin Infect Dis. 2001. PMID: 11979125 Review.
-
[American cutaneous leishmaniasis].Rev Soc Bras Med Trop. 2003 Jan-Feb;36(1):71-80. doi: 10.1590/s0037-86822003000100011. Epub 2003 Apr 22. Rev Soc Bras Med Trop. 2003. PMID: 12715066 Review. Portuguese.
References
-
- Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2006;100(1):S26–S33. - PubMed
-
- Prates FVO, Dourado MEF, Silva SC, Schriefer A, Guimarães LH, Brito MGO. Fluconazole in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis a randomized controlled trial. Clin Infect Dis. 2017;64(1):67–71. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources